Product Introduction
Name:Retatrutride
Product Benefits:Improved blood sugar control
CAS:2381089-83-2
Capacity:5mg/vial
Product Form:White or off-white powder(Peptides)
Shelf Life:2-3Years(The product packaging date shall prevail)
What is Peptide Retatrutride?
**Retatrutide** (development code LY3437943) is a novel peptide drug developed by Eli Lilly for the treatment of obesity, type 2 diabetes, and metabolic syndrome-related diseases. Retatrutide is a multi-receptor agonist that combines the effects on the glucagon-like peptide-1 receptor (GLP-1R), glucagon receptor (GCGR), and glucose-dependent insulinotropic polypeptide receptor (GIPR). It exhibits unique therapeutic potential by synergistically regulating metabolism, promoting weight loss, and improving blood sugar control.
The following is a detailed description of Retatrutide:
### **Physical and chemical properties**
1. **Chemical properties**:
- Retatrutide is a synthetic peptide composed of modified sequences of natural hormones GLP-1, GIP, and glucagon.
- Its chemical structure is designed as a long-acting peptide to optimize bioavailability and prolong drug efficacy.
- It is a high molecular weight peptide and is mainly administered by subcutaneous injection.
2. **Physical properties**:
- Molecular weight: Approximately 4,000 to 6,000 Da (depending on the modification).
- Solubility: Soluble in water and buffer, but poorly soluble in organic solvents.
- Stability: Retatrutide is relatively stable in biological environments and has been structurally modified to reduce enzymatic hydrolysis.
### **Mechanism of action**
1. **GLP-1R agonism**:
- By acting on the GLP-1 receptor, Retatrutide can promote insulin secretion, inhibit glucagon release, and delay gastric emptying, thereby improving blood sugar control.
- GLP-1R agonism also suppresses appetite and helps lose weight.
2. **GCGR agonism**:
- By activating the glucagon receptor, it increases fat decomposition and energy expenditure, further enhancing the weight loss effect.
- GCGR agonism can also promote the decomposition of liver fat and improve non-alcoholic fatty liver disease (NAFLD).
3. **GIPR agonism**:
- Activation of GIP receptors can synergistically enhance insulin secretion, reduce insulin resistance, and have a positive effect on appetite regulation and weight control.
Through the synergistic action of these three receptors, Retatrutide significantly improves metabolic disorders and shows excellent weight loss and glucose control effects.
### **Dosage and administration method**
1. **Dosage**:
- Retatrutide is administered by weekly subcutaneous injection in clinical trials, and the dosage range is usually 0.5-12 mg.
- The starting dose is low (such as 1-2 mg/week), and gradually increased to the target dose to reduce the occurrence of gastrointestinal adverse reactions.
2. **Dosage frequency**:
- Subcutaneous injection once a week is the currently recommended dosing frequency.
### **Half-life and pharmacokinetics**
1. **Half-life**:
- Retatrutide has a long half-life of about 5-7 days, which supports a once-weekly dosing regimen.
- Long-acting property comes from its structural modification, which prolongs the retention time in plasma and reduces the clearance rate of kidney and enzyme.
2. **Pharmacokinetics**:
- Absorption: After subcutaneous injection, it is absorbed slowly, and the blood concentration reaches the peak within 24 to 48 hours.
- Distribution: The distribution volume is low, and it mainly acts on target receptor tissues such as the pancreas, liver and central nervous system.
- Excretion: It is mainly metabolized by the liver and kidneys.
### **Treatment cycle and effect**
1. **Treatment cycle**:
- The recommended treatment cycle is at least 16 to 48 weeks to evaluate the long-term effects of weight loss and metabolic improvement.
- The cycle can be extended according to the individual's metabolic situation and weight loss goals.
2. **Effect**:
- **Weight loss**: Clinical trials have shown that at high doses (12 mg/week), Retatrutide can reduce the average weight of patients by 20 to 24%.
- **Glycemic control**: For patients with type 2 diabetes, Retatrutide significantly reduces HbA1c levels and improves blood sugar fluctuations.
- **Fat metabolism**: Reduces liver fat content and has potential benefits for non-alcoholic fatty liver disease and other metabolic diseases.
### **Adverse reactions**
1. **Common adverse reactions**:
- Gastrointestinal symptoms: nausea, vomiting, diarrhea and constipation.
- Decreased appetite: May cause mild malnutrition, need to monitor food intake.
- Injection site reactions: such as mild redness or pain.
2. **Rare adverse reactions**:
- Pancreatitis: GLP-1 receptor agonists may increase the risk of pancreatitis.
- Thyroid tumor risk: In animal studies, it is associated with GLP-1 agonists, but not confirmed in humans.
### **Precautions**
1. **Contraindications**:
- Patients with a history of pancreatitis should use with caution.
- Patients allergic to peptide drugs are prohibited.
- Pregnant and lactating women should avoid use.
2. **Drug interactions**:
- When used in combination with other glucose-lowering drugs (such as insulin), attention should be paid to the risk of hypoglycemia.
- The effect of delaying gastric emptying may affect the absorption of oral drugs.
### **Clinical prospects and research progress**
1. **Weight loss field**: Retatrutide is considered to be one of the most promising weight loss drugs at present, and its weight loss effect is better than existing GLP-1 agonists (such as semaglutide) in clinical trials.
2. **Metabolic syndrome treatment**: Retatrutide's multi-target effects on a variety of metabolic-related diseases (such as diabetes, hyperlipidemia and fatty liver) make it a potential all-round treatment option.
3. **Development stage**: Currently in Phase III clinical trials, it is expected to be approved and put on the market in the next few years.
### Summary
Retatrutide is a long-acting, multi-target peptide drug that significantly improves obesity, type 2 diabetes and metabolic disorders by activating the synergistic effects of GLP-1, GIP and glucagon receptors. Its long-lasting effect, significant weight loss effect, and good glucose control properties make it full of potential in clinical medicine and obesity treatment. However, it should be used with caution and possible side effects should be strictly monitored.
How peptide retatrutride works
### **Retatrutide Introduction**
Retatrutide is a new type of peptide drug currently being developed by Eli Lilly and is mainly used to treat obesity, type 2 diabetes and related metabolic diseases. It is a multi-agonist that can act on three different receptors simultaneously - GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon receptor. This multiple mechanism of action makes it show significant effects in weight management and metabolic improvement.
### **Applicable population**
Retatrutide is mainly suitable for the following populations:
1. **Obese or overweight patients**
- Applicable to obese patients with a body mass index (BMI) ≥30 kg/m², or overweight patients with a BMI ≥27 kg/m² and complications related to weight (such as hypertension, type 2 diabetes, hyperlipidemia).
2. **Type 2 diabetes patients**
- Applicable to patients with type 2 diabetes who need to improve blood sugar control and may need weight management.
3. **Patients with fatty liver (NAFLD/NASH)**
- It has the potential to reduce fatty liver and improve metabolic parameters, and its efficacy in non-alcoholic steatohepatitis (NASH) is being studied.
4. **People who need to lose weight but other methods are ineffective**
- For example, patients who do not respond to lifestyle interventions (diet and exercise) or other drug treatments.
**Note:**
- It has not been clearly recommended for patients with type 1 diabetes.
- It is not suitable for patients with severe gastrointestinal diseases or allergies to similar peptide drugs (such as semaglutide).
### **How it works**
Retatrutide is a **GLP-1/GIP/glucagon** triple agonist that works mainly through the following mechanisms:
1. **Suppress appetite and reduce food intake**
- It acts on the central nervous system through GLP-1 and GIP receptors to regulate satiety signals and reduce food intake.
2. **Increase energy expenditure**
- Stimulate basal metabolic rate and promote fat decomposition and consumption by stimulating glucagon receptors.
3. **Improve blood sugar metabolism**
- GLP-1 and GIP work together to enhance insulin secretion (glucose-dependent), reduce postprandial blood sugar, and reduce glucose production in the liver.
4. **Reduce fat storage**
- Reduce visceral fat and subcutaneous fat, which helps improve metabolic diseases (such as fatty liver).
This multiple mechanism makes Retatrutide more effective than single-mechanism drugs in weight management and metabolic improvement.
### **Usage and Dosage**
1. **Dosage form**
Retatrutide is usually made into a subcutaneous injection, which is injected once a week (the same as similar drugs such as semaglutide).
2. **Dose adjustment**
- Initial dose: 0.5 mg, once a week.
- Incremental dose: gradually increase to 1.5 mg, 3 mg or higher, and gradually adjust according to the patient's tolerance (usually increase the dose once every 4 weeks).
- Maintenance dose: up to 4.5 mg/week may be possible depending on individual needs.
3. **Precautions for use**
- Each injection should be given at the same time as much as possible to ensure stable efficacy.
- It can be injected with or on an empty stomach, without dietary restrictions.
- Avoid rapid dose increases to reduce common gastrointestinal side effects (such as nausea and vomiting).
### **Common side effects**
1. **Gastrointestinal reactions**
- Nausea, vomiting, diarrhea, or constipation. Usually gradually alleviated as the body adapts.
2. **Hypoglycemia**
- The risk of hypoglycemia is low when used alone, but it may increase the risk when used in combination with insulin or sulfonylureas.
3. **Other side effects**
- Fatigue, dizziness, injection site reactions, etc.
**Serious side effects (need to be vigilant):**
- Pancreatitis or cholecystitis (symptoms: persistent abdominal pain).
- Thyroid tumors (risks observed in animal experiments, further research is needed).
### **Clinical effects and prospects**
In the latest clinical trials (such as the SURMOUNT series of studies), Retatrutide has shown significant effects in weight loss and metabolic improvement:
- Weight loss can reach more than 24% in 52 weeks (depending on the dose).
- It has potential benefits for blood sugar control, improvement of fatty liver and other metabolic diseases.
Related benefits of peptide Retatrutride
Retatrutide (LY3437943) is an experimental peptide drug developed by Eli Lilly and Company. As a triple agonist of GLP-1, GIP and glucagon receptors, it is designed to regulate energy metabolism through multiple mechanisms and show potential benefits in many aspects.
**1. Significant weight loss effect**
In a Phase 2 clinical trial of obese or overweight adults, after 48 weeks of treatment with the highest dose (12 mg) of Retatrutide, the subjects lost an average of 24.2% of their body weight, or about 54 kilograms. All subjects who received 8 mg or 12 mg lost at least 5% of their body weight, of which more than 90% lost more than 10%, nearly two-thirds lost more than 20%, and some even lost more than 30%.
**2. Improved blood sugar control**
Retatrutide also showed a positive effect on blood sugar control in patients with type 2 diabetes. In a study, patients with type 2 diabetes treated with different doses of Retatrutide for 6 months had a reduction in glycated hemoglobin (HbA1c) levels of 1.3% to 2.0%, accompanied by weight loss.
**3. Potential treatment for non-alcoholic fatty liver disease (NAFLD)**
Among patients with non-alcoholic fatty liver disease treated with Retatrutide, 90% of patients had their liver fat content restored to normal levels after 48 weeks of high-dose treatment, suggesting that Retatrutide may have therapeutic potential for NAFLD.
**4. Multiplicity of mechanisms of action**
Retatrutide may produce synergistic effects and enhance weight loss and metabolic improvement effects by activating GLP-1, GIP and glucagon receptors simultaneously. This multiple mechanism of action may give it a unique advantage in weight loss and metabolic disease treatment.
**5. Safety and tolerability**
Clinical trial results showed that the overall safety and tolerability of Retatrutide were similar to those of GLP-1 receptor agonists used for obesity treatment. Common adverse reactions include mild to moderate gastrointestinal symptoms such as nausea and vomiting, but these symptoms can usually be alleviated by gradually increasing the dose.
It should be noted that although Retatrutide has shown significant weight loss and metabolic improvement effects in clinical trials, it is still in the research stage and has not yet been approved by regulators for clinical treatment. Future studies will further evaluate its long-term safety and effectiveness.
Contact Details(WhatsApp Telegram ) And Payment Methods
WhatsApp/Telegram:+852 6749 2648
Gmail:lucasraws207@gmail.com
Skype：live:.cid.8f21dc7fc6621ba7
FAQ
Q: What are the main indications for Retatrutride?
A: Retatrutride is mainly used to treat obesity, type 2 diabetes, and related metabolic disorders. It provides a comprehensive treatment for these diseases by improving insulin sensitivity, reducing body weight, and regulating metabolic status. In addition, studies have also shown that it may have potential therapeutic effects on non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease.
Q: What is the mechanism of action of Retatrutride?
A: Retatrutride works through the following pathways:
1. **GLP-1 receptor stimulant**: promotes insulin secretion, inhibits glucagon secretion, and slows gastric emptying, thereby lowering blood sugar and increasing satiety.
2. **GIP receptor stimulant**: enhances insulin secretion and has a regulatory effect on fat metabolism and storage.
3. **Glucagon receptor stimulant**: increases energy consumption and lipolysis, further promoting weight loss.
The characteristics of multi-target activation make Retatrutride synergistic in metabolic regulation, which can effectively control blood sugar and significantly reduce weight.
Hot Tags: peptides retatrutride 5mg cas：2381089-83-2, China peptides retatrutride 5mg cas：2381089-83-2 manufacturers, suppliers, factory, TB500 Improve muscle tension, Ipamorelin CAS 170851 70 4, PT141 CAS 32780 32 8, Ipamorelin Protect muscle tissue, Sermorelin CAS 86168 78 7, MGF Promote muscle repair and accelerate fat burning
